Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
34.73
-1.05 (-2.93%)
Aug 11, 2026, 11:43 AM EDT - Market open
Roivant Sciences Balance Sheet
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 1,248 | 1,419 | 2,715 | 6,495 | 1,677 | 2,060 |
Short-Term Investments | 2,594 | 2,873 | 2,171 | - | - | - |
Cash & Short-Term Investments | 3,842 | 4,292 | 4,887 | 6,495 | 1,677 | 2,060 |
Cash Growth | -14.68% | -12.18% | -24.76% | 287.34% | -18.62% | 0.26% |
Other Receivables | 771.63 | 770.24 | - | - | - | - |
Total Trade Receivables | 771.63 | 770.24 | - | - | - | - |
Other Current Assets | 128.37 | 105.32 | 113.17 | 236.88 | 121.77 | 86.12 |
Total Current Assets | 4,742 | 5,167 | 5,000 | 6,732 | 1,799 | 2,147 |
Net Property, Plant & Equipment | 90.21 | 92.4 | 101.08 | 59.32 | 92.34 | 86.95 |
Other Intangible Assets | - | - | - | - | 144.88 | - |
Long-Term Investments | 444.62 | 407.99 | 302.94 | 247.75 | 304.32 | 325.83 |
Other Long-Term Assets | 29.59 | 40.92 | 32.86 | 183.58 | 49.48 | 25.82 |
Total Assets | 5,306 | 5,709 | 5,437 | 7,222 | 2,390 | 2,585 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 25.08 | 18 | 23.69 | 14.03 | 37.83 | 34.58 |
Accrued Expenses | 242.92 | 251.51 | 114.71 | 119.42 | 167.13 | 127.53 |
Current Portion of Long-Term Debt | - | - | - | - | 40.72 | - |
Current Portion of Leases | 12.38 | 11.15 | 9.84 | 8.97 | 11.69 | 11.4 |
Other Current Liabilities | 3.21 | 0.58 | 1.17 | 124.35 | 15.08 | 10.86 |
Total Current Liabilities | 283.6 | 281.24 | 149.41 | 266.76 | 272.45 | 184.37 |
Long-Term Debt | - | - | - | - | 375.52 | 210.03 |
Long-Term Leases | 94.77 | 96.29 | 90.33 | 45.02 | 53.48 | 62.47 |
Other Long-Term Liabilities | 6.25 | 38.74 | 10 | 462.18 | 80.58 | 66.84 |
Total Long-Term Liabilities | 101.02 | 135.03 | 100.33 | 507.2 | 509.57 | 339.33 |
Total Liabilities | 384.62 | 416.28 | 249.74 | 773.95 | 782.02 | 523.7 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Additional Paid-in Capital | 5,131 | 5,025 | 4,562 | 5,396 | 4,933 | 4,422 |
Accumulated Other Comprehensive Income | 0.7 | 4.36 | 9.44 | -4.08 | -2.62 | -0.95 |
Retained Earnings | -900.35 | -501.81 | 116.06 | 576.17 | -3,773 | -2,764 |
Total Common Shareholders' Equity | 4,231 | 4,527 | 4,688 | 5,969 | 1,158 | 1,657 |
Minority Interest | 690.6 | 765.04 | 499.59 | 479.95 | 449.82 | 404.49 |
Shareholders' Equity | 4,922 | 5,292 | 5,187 | 6,449 | 1,608 | 2,061 |
Total Liabilities & Equity | 5,306 | 5,709 | 5,437 | 7,222 | 2,390 | 2,585 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 107.15 | 107.44 | 100.17 | 53.99 | 481.4 | 283.89 |
Net Cash (Debt) | 3,735 | 4,184 | 4,787 | 6,441 | 1,195 | 1,777 |
Net Cash Growth | -15.18% | -12.58% | -25.68% | 438.81% | -32.71% | -1.85% |
Net Cash Per Share | 5.13 | 6.03 | 6.60 | 7.75 | 1.68 | 2.65 |
Book Value | 4,231 | 4,527 | 4,688 | 5,969 | 1,158 | 1,657 |
Book Value Per Share | 5.81 | 6.52 | 6.46 | 7.18 | 1.62 | 2.47 |
Tangible Book Value | 4,231 | 4,527 | 4,688 | 5,969 | 1,013 | 1,657 |
Tangible Book Value Per Share | 5.81 | 6.52 | 6.46 | 7.18 | 1.42 | 2.47 |